XML 17 R29.htm IDEA: XBRL DOCUMENT v2.4.0.8

License and Collaboration Agreements - License, Collaboration and Other Revenue (Detail) (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
License And Collaboration Agreements [Line Items]
License, collaboration, and other revenue	$ 8,081	$ 6,476
Roche [Member] | PEGASYS and MIRCERA [Member]
License And Collaboration Agreements [Line Items]
License, collaboration, and other revenue	3,197	2,625
Amgen, Inc. [Member] | Neulasta [Member]
License And Collaboration Agreements [Line Items]
License, collaboration, and other revenue	1,250	1,285
Bayer Healthcare LLC [Member] | BAY41-6551 (Amikacin Inhale) [Member]
License And Collaboration Agreements [Line Items]
License, collaboration, and other revenue	752	714
Baxter Healthcare [Member] | BAX 855 (Hemophilia) [Member]
License And Collaboration Agreements [Line Items]
License, collaboration, and other revenue	337	700
Other [Member]
License And Collaboration Agreements [Line Items]
License, collaboration, and other revenue	$ 2,545	$ 1,152

X

- Details

Name:	nktr_LicenseAndCollaborationAgreementsLineItems
Namespace Prefix:	nktr_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Revenue may contain one or more of the following elements: upfront fees, contract research, milestone payments, manufacturing and supply, royalties, and license fees.

+ References

No definition available.

+ Details

Name:	nktr_LicenseCollaborationOtherRevenue
Namespace Prefix:	nktr_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration